Tipp

Gastric and esophageal cancer: Post ASCO 2015

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 4/2015

Autor:: MD Ewald Wöll

Abstract

Immunologic tumor therapy was the leading theme of this year’s ASCO. In this context first results for check point inhibitors active in esophageal and gastric cancer were presented. Phase III trials involving c-met inhibitors however were not successful. First phase II results with regorafenib emphasize a potential role for TKI’s in gastric cancer.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Alderson D, Langley RE, Nankivell MG, Blazeby JM, Griffin M, Crellin A, et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). J Clin Oncol 33, 2015. (suppl; abstr 4002).

Pauligk C, Tannapfel A, Meiler J, Luley KB, Kopp HG,Homann N, et al. Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. J Clin Oncol 33, 2015. (suppl; abstr 4016).

Wöll E. Perioperative therapy in gastric cancer. Memo 1 71 -73, 2008

Ajani J, Rodriguez W, Bodoky G, Moiseyenko V, Lichiniteser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28:1547-1553, 2010.

Ajani JA, Abramov M, Bondar V, Bondarenko I, Shparyk YV, Gorbunova V, et al. Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial). J Clin Oncol 33, 2015. (suppl; abstr 4015).

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet 376: 687-697, 2010.

Enzinger PC, Abrams TA , Chan JA, McCleary NJ, Zheng H, Kwak EL, et al. Multicenter phase 2: Capecitabine (CAP) + oxaliplatin (OX) + bevacizumab (BEV) + trastuzumab (TRAS) for patients (pts) with metastatic esophagogastric cancer (MEGCA). J Clin Oncol 33, 2015. (suppl; abstr 4038).

Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, Donehower RC et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 30: 2012. (suppl; abstr 4005).

Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 33, 2015. (suppl; abstr 4000).

10.

Shah MA, Bang YJ, Lordick F, Tabernero J, Chen M, Hacket SP al. METGastric: A phase III study of 10.1007/s12254-015-0227-3 onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). J Clin Oncol 33, 2015. (suppl; abstr 4012).

11.

Bang YJ, Chung HC, Shankaran V, Geva R, Catenacci DVT, Gupta S, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol 33, 2015. (suppl; abstr 4001).

12.

Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H,Yuan S, Koshiji M et al. Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028. J Clin Oncol 33, 2015. (suppl; abstr 4010).

Titel: Gastric and esophageal cancer: Post ASCO 2015
Autor:: MD Ewald Wöll
Publikationsdatum: 01.12.2015
DOI: https://doi.org/10.1007/s12254-015-0227-3
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 4/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Biomarkers—hope and hype

ASCO 2015: Highlights in breast cancer

Soft tissue sarcomas & GIST Insights into subtype-specific therapy concepts: Highlights from ASCO meeting 2015

Exosomes as novel biomarkers in anticancer therapy

Thermoablation: a new treatment option to replace surgical intervention?

Obituary for Dr. Ferdinand Ploner